Incyte: INCB123667 with bevacizumab shows promising activity in ovarian cancer
Incyte reported preliminary data for INCB123667 plus bevacizumab in ovarian cancer, with a phase 3 study planned for 2026, per TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, INCB123667 combined with bevacizumab showed preliminary activity in heavily pretreated patients with platinum-resistant ovarian cancer. The objective response rate was 48%, disease control reached 91%, and median progression-free survival was 7.4 months.
The safety profile was described as manageable. The company plans to start a phase 3 first-line maintenance study in 2026.
why it matters
For Incyte shares, the data support the oncology pipeline, but the results are preliminary and a phase 3 study will be needed to judge the drug's full potential.
tags
instruments
sources
- INCY: INCB123667 plus bevacizumab showed promising activity; phase 3 maintenance study planned for 2026 — TradingView, 24 October 2026 at 05:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗